Cardinal Health Inc (CAH) · Nov 5, 2026 · Earnings

Cardinal Health earnings beat as FY27 EPS guidance rises

Beat — Non-GAAP EPS $3.26 vs ~$2.95 consensus

Cardinal Health’s Q1 earnings beat published expectations and lifted FY27 EPS guidance, though its medical distribution turnaround remains uneven.

Cardinal Health is still being driven by its Pharmaceutical and Specialty Solutions business, while it works through a multi-year improvement plan in Global Medical Products and Distribution (GMPD). Its fiscal 2026 strategy emphasized specialty growth, expansion of smaller growth businesses, and GMPD operational simplification and cost reduction.

The quarter beat the published bar and raised the full-year outlook. Non-GAAP diluted EPS reached $3.26 versus published consensus of roughly $2.95, while revenue was $67.5 billion versus about $66.6 billion expected. The more important change is forward-looking: management lifted FY27 non-GAAP EPS guidance to $12.80–$13.00 from $12.40–$12.60.

FigureQ1 FY27Q1 FY26Consensus / prior guide
Non-GAAP diluted EPS (Financial Highlights)$3.26 (+28%)$2.55$2.95 consensus
Revenue (Financial Highlights)$67.5B (+5%)$64.0B$66.6B consensus
Pharmaceutical & Specialty Solutions profit (Segment results)$783M (+17%)$667M
GMPD segment profit (Segment results)$33M (-28%)$46M
FY27 non-GAAP EPS outlook (Guidance)$12.80–$13.00$12.40–$12.60 prior guide

The core earnings engine is outperforming, not merely benefiting from accounting noise. Pharmaceutical and Specialty Solutions profit rose 17%, helped by branded and specialty products and the generics program, while consolidated non-GAAP operating earnings increased 17% to $1.0 billion.

GMPD remains the clear weak spot. Revenue was roughly flat and segment profit fell 28% to $33 million because of unfavorable distribution and foreign-exchange impacts. That does not overturn the broader result, but it shows the turnaround is still incomplete and leaves less room for execution misses in the medical-products business.

The CVS renewal is important strategically but not fresh news today. Cardinal Health had already disclosed the binding letter of intent in October, including continuation of the relationship through June 2032, so this filing mainly confirms the agreement while the earnings and guidance raise provide the new information. 〔0〕

Bottom line: This is a clearly stronger-than-expected start to FY27, with the main growth engine delivering enough upside to lift the full-year target. GMPD is still under pressure, but its weakness is outweighed by the earnings beat and raised outlook.

What to watch next

Q2 FY27 earnings report

Original filing on SEC EDGAR

More Cardinal Health Inc news

Cardinal Health earnings beat as FY27 EPS guidance rises | CAH Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.